UNSPSC 51333407: Mafoprazine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7UUO54C6N. European Medicines Agency schedules Mafoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08634MIG. Mafoprazine generally arises in the molecular formula C22H28FN3O3.

UNSPSC 51333407 Mafoprazine is a Commodity code that in recent state and local solicitations covers the procurement of pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment arrangements. State and local governments buying under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving participating jurisdictions across multiple states. The work involves competitive procurement of pharmaceutical inventory to support community health initiatives, emergency response programs, and state employee and beneficiary prescription benefit programs, with vendors responsible for product sourcing, compliance certification, supply chain management, and delivery logistics.

Recent activity spans Florida, Texas, and Minnesota through a multistate cooperative. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (though the posted date of June 30, 2026 suggests a data inconsistency in the source), requiring unit pricing, drug-free workplace certification, E-Verify compliance, and fixed-fee contracting with a two-year term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, seeking vendor experience with self-insured employers and government health plans and flexibility on negotiated net pricing. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026; pricing will be weighted at 75 percent, with vendors required to maintain $5 million commercial general liability and $2 million network security and professional liability insurance and comply with cGMP and Drug Supply Chain Security Act certification.